TECH · BIO-TECHNE Corp · Financials
Market Cap
$11.36B
Shares
156.82M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.22B
-0.4%
FY2026
Net Income
$181.86M
+147.8%
FY2026
Gross Margin
65.77%
+1pp
FY2026
Operating Margin
20.73%
+12.4pp
FY2026
Diluted EPS
$1.16
+152.2%
FY2026
Operating Cash Flow
$292.07M
+1.6%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.22B | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M | $714.01M | $642.99M | $563M | $499.02M | $452.25M | $357.76M | $310.58M | $314.56M | $289.96M | $269.05M | $263.96M | |
| $415.97M | $429.36M | $389.34M | $366.89M | $349.1M | $298.18M | $255.5M | $240.52M | $210.85M | $188.46M | $162.36M | $144.97M | $106.35M | $79.47M | $78.76M | $65.03M | $54.9M | $55.92M | |
| $799.07M | $790.27M | $769.73M | $769.82M | $756.5M | $632.85M | $483.19M | $473.49M | $432.14M | $374.54M | $336.66M | $307.28M | $251.41M | $231.11M | $235.8M | $224.94M | $214.15M | $208.03M | |
| 65.77% | 64.8% | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.6% | 78.81% | |
| $94.77M | $99.5M | $96.66M | $92.49M | $87.14M | $70.6M | $65.19M | $62.41M | $55.33M | $53.51M | $45.19M | $40.85M | $30.95M | $29.26M | $27.91M | $25.99M | $25.12M | $23.56M | |
| $452.42M | $588.52M | $466.38M | $378.38M | $372.77M | $324.95M | $260.58M | $264.36M | $240.64M | $200.44M | $140.88M | $119.4M | $60.72M | $43.38M | $41.68M | $35.9M | $32.7M | $33.69M | |
| $61.79M | $76.04M | $79.85M | $77.49M | $74.15M | $64.94M | $61.1M | $58.72M | $47.08M | $44.39M | $29.4M | — | — | — | — | — | — | — | |
| $97.36M | $109.9M | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M | $78.17M | $64.46M | $60.04M | $42.76M | $37.23M | $19.18M | $12.32M | $12.47M | $8.7M | $8.13M | $7.77M | |
| — | — | $12.25M | $3.83M | $1.64M | $142K | $87K | — | $376K | — | — | — | — | — | — | — | — | — | |
| $547.18M | $688.02M | $563.04M | $470.87M | $459.91M | $395.55M | $325.78M | $326.77M | $295.97M | $253.96M | $186.07M | $160.25M | $91.66M | $72.64M | $69.6M | $61.88M | $57.82M | $57.25M | |
| $251.89M | $102.26M | $206.69M | $298.94M | $296.59M | $237.3M | $157.42M | $146.72M | $136.18M | $120.58M | $150.59M | $147.02M | $159.75M | $158.47K | $166.21M | $163.06M | $156.33M | $150.78M | |
| 20.73% | 8.38% | 17.83% | 26.3% | 26.83% | 25.49% | 21.31% | 20.55% | 21.18% | 21.42% | 30.18% | 32.51% | 44.65% | 0.05% | 52.84% | 56.23% | 58.1% | 57.12% | |
| $349.25M | $212.16M | $318.4M | $406.18M | $397.66M | $325.04M | $240.16M | $224.89M | $200.64M | $180.62M | $193.36M | $184.25M | $178.93M | $12.48M | $178.68M | $171.76M | $164.46M | $158.55M | |
| $9.63M | $8.51M | $15.74M | $11.22M | $11.31M | $13.95M | $19.2M | $21.71M | $10.19M | $7.36M | $1.75M | $1.54M | $0 | $0 | — | — | — | — | |
| -$11.21M | -$3.79M | -$21M | $39.72M | $4.8M | -$89.12M | $119.06M | -$34.7M | -$10.23M | -$8.62M | -$3.11M | $7.14M | $1.64M | $2.19M | -$4.01M | $1.93M | $118K | $4.58M | |
| $887K | $938K | -$6.84M | -$1.14M | — | — | — | — | — | — | — | $0 | $0 | $570K | -$603K | -$926K | -$1.51M | -$1.29M | |
| -$5.86M | — | $283K | $49.33M | $15.19M | -$68.05M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $240.68M | $98.46M | $185.69M | $338.66M | $301.39M | $148.18M | $276.48M | $112.02M | $125.95M | $111.96M | $147.48M | $154.16M | $161.39M | $160.66M | $162.2M | $164.98M | $156.45M | — | |
| $58.82M | $25.06M | $17.58M | $53.22M | $38.29M | $8.59M | $47.18M | $15.94M | -$198K | $35.88M | $43.01M | $46.43M | $50.44M | $48.1M | $49.86M | $52.68M | $46.67M | $50.12M | |
| $181.86M | $73.4M | $168.11M | $285.26M | $272.05M | $140.41M | $229.3M | $96.07M | $126.15M | $76.09M | $104.48M | $107.74M | $110.95M | $112.56M | $112.33M | $112.3M | $109.78M | $105.24M | |
| 14.97% | 6.02% | 14.5% | 25.1% | 24.61% | 15.08% | 31.04% | 13.46% | 19.62% | 13.51% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.8% | 39.87% | |
| — | — | — | $179K | -$8.95M | -$825K | $0 | $0 | — | — | — | — | — | — | — | — | — | — | |
| $181.84M | $73.36M | $168.07M | $285.19M | $271.93M | $140.32M | $229.07M | $95.97M | $126.04M | $76.02M | $104.42M | — | — | — | — | — | — | — | |
| $171.16M | $91.84M | $155.85M | $294.4M | $254.14M | $180.32M | $215.62M | $82.05M | $130.27M | $97.56M | $64.66M | $82.53M | $91.01M | $105.34M | $150.4M | $117.25M | $96.02M | $85.64M | |
| USD/shares | $1.17 | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 | $0.64 | $0.84 | $0.51 | $0.70 | $0.73 | $0.75 | $0.77 | $0.76 | $0.76 | $0.74 | $0.70 |
| USD/shares | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | $0.51 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.74 | $0.70 |
| shares | 155.96M | 157.52M | 157.71M | 157.18M | 156.87M | 154.99M | 152.8M | 151.12M | 149.9M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M |
| shares | 157.01M | 159.72M | 160.77M | 161.86M | 164.11M | 161.93M | 157.6M | 155.57M | 152.22M | 150M | 149.3M | 148.92M | 148.02M | 147.6M | 148.02M | 148.69M | 149.39M | 151.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2026: $819.62M in buybacks, $824.24M in dividends.
Debt Profile
Completed filing coverage through Feb 4, 2020 · latest terminal result Aug 12, 2026Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
4 filing observations remain unmatched and are excluded from instrument histories.
Debt data is being processed. Please check back later.
6 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 10.26×
EV/EBIT
—
Peer median 30.15×
P/E (TTM)
62.44×
Peer median 20.43×
Peer medians compare against the 137 similar-size Biotechnology companies (of 537 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $874,620,000 | $870,245,000 | $830,902,000 | $845,747,000 | $832,311,000 | $704,564,000 | $555,352,000 | $543,159,000 |
| Diagnostics and Spatial Biology | $336,365,000 | $346,263,000 | $326,392,000 | $292,602,000 | — | — | — | — |
| Diagnostics And Genomics | — | — | — | — | $274,843,000 | $227,744,000 | $184,549,000 | $171,674,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $635,372,000 | $683,230,000 | $657,747,000 | $642,465,000 | $614,107,000 | $502,080,000 | $404,407,000 | $391,191,000 |
| EMEA Excluding UK | $294,222,000 | $266,305,000 | $241,432,000 | $220,230,000 | $219,055,000 | $204,264,000 | $155,289,000 | $155,821,000 |
| China | $104,061,000 | $100,463,000 | $99,467,000 | $113,868,000 | $112,438,000 | $87,556,000 | $68,792,000 | $57,799,000 |
| APAC Excluding Greater China | $85,815,000 | $77,263,000 | $73,904,000 | $73,190,000 | $76,139,000 | $69,013,000 | $60,362,000 | $52,913,000 |
| United Kingdom | $56,284,000 | $54,827,000 | $50,012,000 | $49,457,000 | $48,637,000 | $40,945,000 | $30,411,000 | $34,975,000 |
| Rest of World | $39,285,000 | $37,547,000 | $36,498,000 | $37,492,000 | $35,223,000 | $27,174,000 | $19,430,000 | $21,307,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Consumables | $985,115,000 | $972,286,000 | $928,180,000 | $917,733,000 | $890,874,000 | $751,985,000 | $602,642,000 | $588,979,000 |
| Instruments | $110,632,000 | $112,086,000 | $108,270,000 | $112,085,000 | $120,758,000 | $93,782,000 | $71,462,000 | $67,538,000 |
| Service | $94,301,000 | $111,570,000 | $99,265,000 | $85,784,000 | $71,988,000 | $66,416,000 | $47,459,000 | $38,050,000 |
| Royalty | $24,991,000 | $23,693,000 | $23,345,000 | $21,100,000 | $21,979,000 | $18,849,000 | $17,128,000 | $19,439,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $359,401,000 | $370,353,000 | $354,775,000 | $373,684,000 | $377,623,000 | $330,225,000 | $234,929,000 | $240,919,000 |
| Diagnostics and Spatial Biology | $37,698,000 | $21,324,000 | $24,546,000 | $43,037,000 | — | — | — | — |
| Diagnostics And Genomics | — | — | $24,546,000 | $43,037,000 | $48,977,000 | $38,425,000 | $14,965,000 | $10,079,000 |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | 41.1% | 42.6% | 42.7% | 44.2% | 45.4% | 46.9% | 42.3% | 44.4% |
| Diagnostics and Spatial Biology | 11.2% | 6.2% | 7.5% | 14.7% | — | — | — | — |
| Diagnostics And Genomics | — | — | — | — | 17.8% | 16.9% | 8.1% | 5.9% |
Key facts
CIK
842023
CUSIP
09073M104
13F (30d)
311 filings
310 filers
Visit website
Investor relations